Imaging and therapy with rituximab anti-CD20 immunotherapy in an animal model of central nervous system lym phoma

被引：0
|
作者：
Muldoon, Leslie L. [1 ]
Lewin, Seth J. [1 ]
Dosa, Edit [1 ]
Pagel, Michael A. [1 ]
Doolittle, Nancy D. [1 ]
Neuwelt, Edward A. [1 ]
机构：
[1] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/1538-7445.AM2011-5529
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5529
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Imaging and Therapy with Rituximab Anti-CD20 Immunotherapy in an Animal Model of Central Nervous System Lymphoma
    Muldoon, Leslie L.
    Lewin, Seth J.
    Dosa, Edit
    Kraemer, Dale F.
    Pagel, Michael A.
    Doolittle, Nancy D.
    Neuwelt, Edward A.
    CLINICAL CANCER RESEARCH, 2011, 17 (08) : 2207 - 2215
  • [2] Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab
    Schulz, H
    Pels, H
    Schmidt-Wolf, I
    Zeelen, U
    Germing, U
    Engert, A
    HAEMATOLOGICA, 2004, 89 (06) : 753 - 754
  • [3] Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system
    Tokunaga, Mikiko
    Saito, Kazuyoshi
    Kawabata, Daisuke
    Imura, Yoshitaka
    Fujii, Takao
    Nakayamada, Shingo
    Tsujimura, Shizuyo
    Nawata, Masao
    Iwata, Shigeru
    Azuma, Taeko
    Mimori, Tsuneyo
    Tanaka, Yoshiya
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (04) : 470 - 475
  • [4] Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system.
    Tanaka, Y
    Tokunaga, M
    Kawabata, D
    Imura, Y
    Fujii, T
    Nawata, M
    Tsujimura, S
    Nakayamada, S
    Mimoro, T
    Saito, K
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S191 - S191
  • [5] Complement activation in circulation and central nervous system after Rituximab (Anti-CD20) treatment of B-Cell lymphoma
    Harjunpää, A
    Wiklund, T
    Collan, J
    Janes, R
    Rosenberg, J
    Lee, D
    Grillo-López, A
    Meri, S
    LEUKEMIA & LYMPHOMA, 2001, 42 (04) : 731 - 738
  • [6] Anti-CD20 treatment and neutrophil function in central nervous system demyelinating diseases
    Balazs, Irina
    Horvath, Angela
    Heschl, Bettina
    Khalil, Michael
    Enzinger, Christian
    Stadlbauer, Vanessa
    Seifert-Held, Thomas
    JOURNAL OF NEUROIMMUNOLOGY, 2023, 381
  • [7] Primary central nervous system lymphoma: Current state of anti-CD20 therapy and appraisal of reported response criteria
    Siegal, Tali
    JOURNAL OF CLINICAL NEUROSCIENCE, 2014, 21 (05) : 709 - 715
  • [8] Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myocionus syndrome
    Pranzatelli, Michael R.
    Tate, Elizabeth D.
    Travelstead, Anna L.
    Barbosa, Jerry
    Bergamini, Robert A.
    Civitello, Lucy
    Franz, David N.
    Greffe, Brian S.
    Hanson, Robin D.
    Hurwitz, Craig A.
    Kalinyak, Karen A.
    Fer, Howard Ke
    Khakoo, Yasmin
    Mantovani, John F.
    Nicholson, Stacy H.
    Sanders, Joann M.
    Wegner, Stephen
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2006, 28 (09) : 585 - 593
  • [9] Accelerated progression of multiple myeloma during anti-CD20 (Rituximab) therapy
    Korte, W
    Jost, C
    Cogliatti, S
    Hess, U
    Cerny, T
    ANNALS OF ONCOLOGY, 1999, 10 (10) : 1249 - 1250
  • [10] Ofatumumab is a feasible alternative anti-CD20 therapy in patients intolerant of rituximab
    Chen, Lucia Y.
    Shah, Raakhee
    Cwynarski, Kate
    Lambert, Jonathan
    McNamara, Christopher
    Mohamedbhai, Sajir G.
    Virchis, Andres
    Townsend, William
    D'Sa, Shirley
    Ardeshna, Kirit M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 184 (03) : 462 - 465
12345